Drew Fromkin

Chief Executive Officer

30+ years leadership in public & private healthcare companies; serves as Vant Portfolio Operating Partner. He serves on the Board of Immunovant, Inc. (NASDAQ: IMVT).

Previously: President, CEO and Chairman Tarveda Therapeutics, CEO of Clinical Data (CLDA) ( $1.5 Billion Sale); CEO DoctorQuality (Sold Quantros); CEO Endo Surgical Devices, Head Corp Dev. Merck Medco.